About
TrioxNano's powerhouse created a biosphere of programmed therapeutic/diagnostic solutions based on synthetic DNA molecular machines Our team of exceptional scientists fluent in the secrets of DNA programming & highly skilled execs has led to the development of the Programmed Medicine Biosphere. Granted global all inclusive patents & winning the prestigious H2020 2.7M grant allowed us develop :
P-ADC - Programmable ADCs (Aptamer DNAzyme Conjugates) Technology: Market Challenges: Analog treatments exhibit low efficacy and high toxicity, addressing only 15% of cancer targets. Our Solution: P-ADC replaces analog components with a digital aptamer and programmed DNAzyme, excelling in highly targeted mRNA knockdown. Market Potential: Estimated at $550B, addressing the growing need for precision medicine.
P-DDP - Programmable Drug Delivery Platforms: Market Challanges: Traditional drug delivery lacks precision, leading to low treatment effectiveness and side effects. Our Solution: P-DDP enables precise drug delivery, significantly improving efficacy and reducing side effects. Market Potential: Estimated at $100B, capitalizing on the demand for personalized medicine.
P-DST - Programmable DNA Strip Technology: Market Challanges: Current antigen tests lack sensitivity, specificity, and home-testing capabilities. Our Solution: P-DST revolutionizes antigen testing with a programmable approach, offering at-home testing for thousands of antigens. Market Potential: Annual revenues estimated at $140B, meeting the increasing demand for accurate home diagnostics.
PCPM - Precision Cancer Profiling using mRNA Knockdown Technology: Market Challanges: Current cancer tests lack functional insights, precision, and cost-effectiveness. Our Solution: PCPM provides functional information, cost-effective mRNA profiling, and AI + ML recommendations for a holistic understanding. Market Potential: Exceeding $100B, addressing the rising need for functional cancer diagnostics.
Funding history · 1 round · $3.6M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the current operational status of TrioxNano?
- TrioxNano is currently inactive, having ceased operations in December 2024.
- When was TrioxNano founded?
- TrioxNano was founded in July 2015.
- What was TrioxNano's total amount raised in USD?
- TrioxNano raised a total of $3,600,000 USD.
- When did TrioxNano secure its last funding round?
- TrioxNano secured a Seed funding round in November 2021, raising $500,000.
- Did TrioxNano receive any grants?
- Yes, TrioxNano received a grant of $3,100,000 from the IIA in June 2018.
- How many employees did TrioxNano have?
- TrioxNano had 6 employees.
- What is TrioxNano's primary focus in terms of technology?
- TrioxNano focuses on programmable medicine using synthetic DNA molecular machines, specifically in areas like Programmable ADCs, Programmable Drug Delivery Platforms, Programmable DNA Strip Technology, and Precision Cancer Profiling using mRNA Knockdown Technology.
- Does TrioxNano hold any patents?
- Yes, TrioxNano holds global all-inclusive patents for its technology.